Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos

Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.

DealWatch_1200x675

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

After bringing in $150m in its initial public offering on 15 October, Aligos Therapeutics, Inc. now has taken on a deep-pocketed partner as Merck & Co., Inc. is investing in its oligonucleotide platform to discover and develop novel candidates for non-alcoholic steatohepatitis and an additional target in the cardiometabolic/fibrotic health space

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business